Table of Contents Table of Contents
Previous Page  6 / 18 Next Page
Information
Show Menu
Previous Page 6 / 18 Next Page
Page Background

CM 066: Nivolumab

primera linea

Atkinson V, Ascierto PA, Long GV, et al. Two-Year Survival and Safety Update in Patients With Treatment-Naïve Advanced Melanoma (MEL) Receiving Nivolumab or

Dacarbazine in CheckMate 066. Presented at Society for Melanoma Research (SMR) 2015 International Congress; November 18–21, 2015; San Francisco, California, USA